Bruker (BRKR) continues to grow, banking on its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. The stock carries a Zacks Rank #2 (Buy) currently. Bruker’s CALID Group has been making decent progress lately, primarily because of the strong demand for differentiated instruments. The group is benefiting from sustained growth in the mass spectrometry business, including FT-IR, Near IR and Raman molecular spectroscopy product lines. Bruker’s timsTOF platform con ...